D
Didier Samuel
Researcher at Université Paris-Saclay
Publications - 716
Citations - 38221
Didier Samuel is an academic researcher from Université Paris-Saclay. The author has contributed to research in topics: Liver transplantation & Transplantation. The author has an hindex of 93, co-authored 669 publications receiving 33585 citations. Previous affiliations of Didier Samuel include University of Paris-Sud & South University.
Papers
More filters
Graft-versus-host disease following living donor liver transplantation: high risk when the donor is HLA-homozygous
Guadalupe Garcia-Tsao,Ronald P.J. Oude Elferink,Didier Samuel,James L. Boyer,Hartmut Jaeschke,Luigi Pagliaro,Jorge Rakela,Tania Roskams,Christian Trautwein +8 more
TL;DR: The use of an HLA homozygous donor which results in a complete 1-way donor-recipient HLA match carries an extremely high risk of developing GVHD after LDLT, and it is possible that LDLT should be ruled out for such donors.
Book ChapterDOI
Therapeutic issues in lymphoproliferative disorders: Treatment and outcome of 28 cases observed in a single center
Veronique Leblond,Richard Dorent,Marc-Olivier Bitker,Carole Soussain,Didier Samuel,Jacques-Louis Binet,Martine Raphael +6 more
TL;DR: The experience of 28 transplant recipients with a PTLD was reexamined in an attempt to determine the response to therapy in 25 treated patients with reduction of immunosuppressants, monoclonal antibodies, surgery and/or chemotherapy after a median of follow-up of 60 months.
OtherDOI
Management of Hepatitis B Virus Infection Post Transplantation
Bruno Roche,Didier Samuel +1 more
Journal ArticleDOI
Foie artificiel. Concept et développements actuels
Journal ArticleDOI
Predictive factors of antibody response after anti-SARS-CoV-2 vaccine in liver transplant recipients
Ilias Kounis,Bruno Roche,Léa Duhaut,Rodolphe Sobesky,Eleonora De Martin,E. Poli,Alina Pascale,Gabriella Pittau,Oriana Ciacio,Jean-Charles Duclos-Vallée,Didier Samuel,Cyrille Feray,Audrey Coilly +12 more
TL;DR: A strong immune response was detected to less than a half of LT recipients after 3 doses of anti-SARS-CoV-2 vaccine, and these patients remain at risk for Covid-19, especially in case of high levels of immunosuppression.